PremiumThe FlyAmphastar price target lowered to $35 from $40 at Wells Fargo Cautious Hold Rating for Amphastar Pharmaceuticals Amid Competitive Pressures and Revenue Challenges Amphastar Pharmaceuticals: Neutral Stance Amid Mixed Financial Outlook and Pipeline Uncertainty PremiumCompany AnnouncementsAmphastar’s Earnings Call: Growth Amid Challenges Amphastar price target lowered to $36 from $44 at BofA Amphastar Pharmaceuticals Reports Strong 2024 Earnings PremiumThe FlyCorrection: Amphastar did not report Q4 earnings this morning Amphastar reports Q4 adjusted EPS 55c, consensus 50c Amphastar initiated with an Equal Weight at Wells Fargo 
